Dr. Gulhati is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
195 Little Albany Street
New Brunswick, NJ 08901Phone+1 732-235-3551
Education & Training
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2015 - 2018
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 2014 - 2015
University of Texas Medical Branch School of MedicineClass of 2006
Certifications & Licensure
NJ State Medical License 2019 - 2025
TX State Medical License 2017 - 2021- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Adjuvant Gemcitabine and Capecitabine Chemotherapy in Resected Pancreatic Cancer Following Neoadjuvant Chemotherapy Start of enrollment: 2022 Jul 29
Roles: Contact, Principal Investigator
Publications & Presentations
PubMed
- 135 citationsAkt2 overexpression plays a critical role in the establishment of colorectal cancer metastasisPiotr G. Rychahou, Junghee Kang, Prateek gulhati, Hung Q. Doan, L. Andy Chen
Proceedings of the National Academy of Sciences of the United States of America. 2008-12-23 - 83 citationsThe deubiquitination enzyme USP46 functions as a tumor suppressor by controlling PHLPP-dependent attenuation of Akt signaling in colon cancerXin Li, Payton D. Stevens, H. Yang, Prateek gulhati, W. Wang
Oncogene. 2013-01-24 - 221 citationsmTOR inhibitors in cancer therapyYekaterina Y. Zaytseva, Joseph D. Valentino, Prateek gulhati, B. Mark Evers
Cancer Letters. 2012-06-01
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
